RNA interference in skin indications
First Claim
1. A method for treating compromised skin, the method comprising, administering to a subject a therapeutically effective amount for treating compromised skin of a double stranded nucleic acid molecule comprising a guide strand, with a minimal length of 16 nucleotides, and a passenger strand forming a double stranded nucleic acid molecule, having a double stranded region and a single stranded region, the double stranded region having 8-15 nucleotides in length, the single stranded region having 4-12 nucleotides in length, wherein position 1 of the guide strand is 5′
- phosphorylated or has a 2′
O-methyl modification, wherein the passenger strand is linked to a lipophilic group, wherein at least 40% of the nucleotides of the double stranded nucleic acid are modified, and wherein the double stranded nucleic acid molecule has one end that is blunt or includes a one nucleotide overhang, wherein the double stranded nucleic acid molecule is directed against a gene encoding Connective Tissue Growth Factor (CTGF), and wherein treating compromised skin comprises preventing, reducing, or inhibiting dermal scarring in compromised skin.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
-
Citations
12 Claims
-
1. A method for treating compromised skin, the method comprising, administering to a subject a therapeutically effective amount for treating compromised skin of a double stranded nucleic acid molecule comprising a guide strand, with a minimal length of 16 nucleotides, and a passenger strand forming a double stranded nucleic acid molecule, having a double stranded region and a single stranded region, the double stranded region having 8-15 nucleotides in length, the single stranded region having 4-12 nucleotides in length, wherein position 1 of the guide strand is 5′
- phosphorylated or has a 2′
O-methyl modification, wherein the passenger strand is linked to a lipophilic group, wherein at least 40% of the nucleotides of the double stranded nucleic acid are modified, and wherein the double stranded nucleic acid molecule has one end that is blunt or includes a one nucleotide overhang, wherein the double stranded nucleic acid molecule is directed against a gene encoding Connective Tissue Growth Factor (CTGF), and wherein treating compromised skin comprises preventing, reducing, or inhibiting dermal scarring in compromised skin. - View Dependent Claims (2, 3, 4, 5, 6)
- phosphorylated or has a 2′
-
7. A method for treating compromised skin, the method comprising, administering to a subject a therapeutically effective amount for treating compromised skin of a double stranded nucleic acid molecule comprising a guide strand, with a minimal length of 16 nucleotides, and a passenger strand forming a double stranded nucleic acid molecule, having a double stranded region and a single stranded region, the double stranded region having 8-15 nucleotides in length, the single stranded region having 4-12 nucleotides in length, wherein position 1 of the guide strand is 5′
- phosphorylated or has a 2′
O-methyl modification, wherein at least 40% of the nucleotides of the double stranded nucleic acid are modified, and wherein the double stranded nucleic acid molecule has one end that is blunt or includes a one nucleotide overhang, wherein the double stranded nucleic acid molecule is directed against a gene encoding Connective Tissue Growth Factor (CTGF), and wherein treating compromised skin comprises preventing, reducing, or inhibiting dermal scarring in compromised skin. - View Dependent Claims (8, 9, 10, 11, 12)
- phosphorylated or has a 2′
Specification